Alumis director buys 986K shares, to return profit
Rhea-AI Filing Summary
ALUMIS INC. (ALMS) director Srinivas Akkaraju, through affiliated funds, reported both purchases and sales of Alumis common stock in early September 2026, with overall net buying activity. On September 8, 2026, Samsara BioCapital, L.P. sold 48,066 shares at a weighted average of $10.5484 and purchased 273,291 shares at a weighted average of $10.6271; Samsara Opportunity Fund, L.P. sold 48,065 shares and purchased 273,290 shares at the same respective weighted average prices.
On September 4, 2026, each of Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. separately purchased 220,070 shares at a weighted average price of $11.1730. A holding line shows 3,553 shares held directly. A footnote states that the September 8, 2026 sales and purchases were matchable under Section 16(b), creating short-swing profit liability, and that the reporting person agreed to disgorge the short-swing profit to Alumis, less transaction costs. Another footnote explains that prices are weighted averages over disclosed intraday price ranges, and that the reporting person disclaims beneficial ownership of fund-held shares except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is indicated.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 890,590 shares
Net Buy
7 txns
Insider
AKKARAJU SRINIVAS
Role
Director
Bought
986,721 shs ($10.73M)
Sold
96,131 shs ($1.01M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F4, F5, F2 | 48,066 | $10.5484 | $507K |
| Sale | Common Stock F4, F5, F3 | 48,065 | $10.5484 | $507K |
| Purchase | Common Stock F4, F6, F2 | 273,291 | $10.6271 | $2.90M |
| Purchase | Common Stock F4, F6, F3 | 273,290 | $10.6271 | $2.90M |
| Purchase | Common Stock F1, F2 | 220,070 | $11.173 | $2.46M |
| Purchase | Common Stock F1, F3 | 220,070 | $11.173 | $2.46M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 4,937,026 shares (Indirect, By Samsara BioCapital, L.P.);
Common Stock — 2,298,783 shares (Indirect, By Samsara Opportunity Fund, L.P.);
Common Stock — 3,553 shares (Direct)
Footnotes (6)
- F1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- F2. Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F3. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
- F4. The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.
- F5. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F6. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Key Figures
Shares sold on September 8, 2026: 48,066 shares by Samsara BioCapital, L.P.; 48,065 shares by Samsara Opportunity Fund, L.P.
Shares purchased on September 8, 2026: 273,291 shares by Samsara BioCapital, L.P.; 273,290 shares by Samsara Opportunity Fund, L.P.
Weighted average sale price September 8, 2026: $10.5484 per share
+4 more
7 metrics
Shares sold on September 8, 2026
48,066 shares by Samsara BioCapital, L.P.; 48,065 shares by Samsara Opportunity Fund, L.P.
Open market or private sales of Alumis common stock
Shares purchased on September 8, 2026
273,291 shares by Samsara BioCapital, L.P.; 273,290 shares by Samsara Opportunity Fund, L.P.
Open market or private purchases of Alumis common stock
Weighted average sale price September 8, 2026
$10.5484 per share
Sales in multiple trades from $10.38 to $10.91
Weighted average purchase price September 8, 2026
$10.6271 per share
Purchases in multiple trades from $10.26 to $10.835
Shares purchased on September 4, 2026
220,070 shares by each of Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P.
Open market or private purchases at weighted average $11.1730
Direct holding after reported transactions
3,553 shares
Common stock held directly as of September 4, 2026
Aggregate reported purchases and sales
986,721 shares purchased; 96,131 shares sold
Transaction summary for this Form 4
Key Terms
Section 16(b), short-swing profit, weighted average price, disgorge, +1 more
5 terms
Section 16(b) regulatory
"were matchable under Section 16(b) of the Securities Exchange Act of 1934"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
short-swing profit regulatory
"resulting in short-swing profit liability under Section 16(b)"
Short-swing profit is any gain an insider makes from buying and selling (or selling and buying) the same company's stock or options within a six-month window; regulators treat those quick trades as presumptively improper and typically require the profits to be returned. Think of it like flipping a concert ticket for a quick markup — the law prevents insiders with privileged access from keeping those fast gains, which protects ordinary investors and promotes fair markets.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
disgorge regulatory
"has agreed to disgorge to the Issuer the short-swing profit realized"
pecuniary interest financial
"disclaims beneficial ownership of these shares except to the extent of his pecuniary interest"
FAQ
What transactions in ALMS stock did director Srinivas Akkaraju report?
He reported multiple indirect trades in Alumis common stock in September 2026, including sales totaling 96,131 shares and purchases totaling 986,721 shares through Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P., plus a direct holding of 3,553 shares.
What prices were paid and received in the ALMS trades reported?
Reported prices are weighted averages. September 8, 2026 sales used $10.5484 per share, with individual sale prices from $10.38 to $10.91. September 8 purchases used $10.6271 per share, within $10.26 to $10.835. September 4 purchases used $11.1730, within $11.02 to $11.60.
Were the ALMS trades subject to Section 16(b) short-swing profit rules?
Yes. A footnote states the September 8, 2026 sales and purchases were matchable under Section 16(b), resulting in short-swing profit liability, and that the reporting person agreed to disgorge the short-swing profit to Alumis, less transaction costs.
Did the ALMS Form 4 indicate a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as an affirmed plan, and the footnotes describe weighted-average pricing and Section 16(b) treatment but do not state that trades were made under a Rule 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
